- Home
- TGL vs CERO Comparison
TGL vs CERO Comparison
Compare TGL & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- CERO
- Stock Information
- Founded
- TGL 2020
- CERO 2017
- Country
- TGL United States
- CERO United States
- Employees
- TGL N/A
- CERO N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- CERO
- Sector
- TGL Technology
- CERO
- Exchange
- TGL Nasdaq
- CERO Nasdaq
- Market Cap
- TGL 4.1M
- CERO 3.6M
- IPO Year
- TGL 2022
- CERO N/A
- Fundamental
- Price
- TGL $0.74
- CERO $1.88
- Analyst Decision
- TGL
- CERO Strong Buy
- Analyst Count
- TGL 0
- CERO 2
- Target Price
- TGL N/A
- CERO $45.00
- AVG Volume (30 Days)
- TGL 5.5M
- CERO 430.6K
- Earning Date
- TGL 10-15-2025
- CERO 11-18-2025
- Dividend Yield
- TGL N/A
- CERO N/A
- EPS Growth
- TGL N/A
- CERO N/A
- EPS
- TGL N/A
- CERO N/A
- Revenue
- TGL $2,330,557.00
- CERO N/A
- Revenue This Year
- TGL N/A
- CERO N/A
- Revenue Next Year
- TGL N/A
- CERO N/A
- P/E Ratio
- TGL N/A
- CERO N/A
- Revenue Growth
- TGL N/A
- CERO N/A
- 52 Week Low
- TGL $0.70
- CERO $1.81
- 52 Week High
- TGL $39.00
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- TGL 35.68
- CERO 20.20
- Support Level
- TGL $0.73
- CERO $1.93
- Resistance Level
- TGL $1.17
- CERO $2.58
- Average True Range (ATR)
- TGL 0.10
- CERO 0.41
- MACD
- TGL -0.02
- CERO -0.05
- Stochastic Oscillator
- TGL 6.33
- CERO 1.96
About TGL Treasure Global Inc.
Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.